Loading data for KPRX — first visit, this takes a few seconds.
Kiora Pharmaceuticals Inc... (KPRX)
NasdaqCM: KPRX
· Real-Time Price · USD
2.75
+0.09 (3.38%)
At close: Aug 28, 2026, 3:56 PM
2.57
+0.00%
After-hours: 4:10 PM
The price, the headline numbers and the latest news, in one place.
Kiora Pharmaceuticals Inc. (KPRX) Stock Price, Analysis & Data
3.38% (1D)
| Bid | 1.86 |
| Market Cap | 11.59M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -10.99M |
| -0.34 | |
| -2.41 | |
| n/a | |
| -1.17 | |
| P/B (ttm) | 0.75 |
| P/S (ttm) | n/a |
| Earnings Date | n/a |
| Ask | 3.34 |
| Volume | 10,301 |
| Avg. Volume (20D) | 23,444 |
| Open | 2.65 |
| Previous Close | 2.66 |
| Day's Range | 2.65 - 2.75 |
| 52-Week Range | 1.76 - 2.95 |
| Analyst | n/a |
| Price Target | n/a |
| Dividends | n/a |
| Ex-Dividend Date | n/a |
About KPRX
Kiora Pharmaceuticals, Inc., a clinical-stage specialty pharmaceutical company, engages in the development and commercialization of therapies for the treatment of ophthalmic diseases. Its lead product is KIO-301, a potential vision-restoring small molecule, which is in Phase 2 clinical trials for the treatment of retinitis pigmentosa, choroideremia, and Stargardt disease. The company is also developing KIO-104, a non-steroidal, immuno-modulatory,...
Industry Biotechnology
Sector Healthcare
IPO Date Feb 13, 2015
Employees 13
Stock Exchange NasdaqCM
Ticker Symbol KPRX
Website https://www.kiorapharma.com
Financial Performance
In 2025, Kiora Pharmaceuticals's revenue was 0, a decrease of -100% compared to the previous year's 16M. Earnings were -10.84M, a decrease of -401.42%.
Financial StatementsEarnings Surprise
Kiora Pharmaceuticals has released their quarterly earnings on Aug 7, 2026:
- Revenue of $0 misses estimates by $0, with NaN% YoY growth.
- EPS of -0.34 exceeds estimates by 0.28, with 37.04% YoY growth.
